

## Summary attachment – SWEAML12a trial

The SWEAML-12 trial was prematurely terminated due to slow recruitment and upcoming competing trials. After three years active recruitment only eleven subjects were included. The sponsor hence decided to terminate the trial. The last included patient was included 2014-05-21 and the last patient follow up within the trial was at 2015-01-23. No SUSAR:s were reported. SAE:s were mostly in the comparator arm (standard treatment according to Swedish national guidelines) and were of the expected kind with febrile neutropenia. Due to the low number of participants no outcome analyses were performed.